Navigation Links
Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Fourth Quarter and Full Year Financial Results
Date:2/23/2010

$(15,417) $(82,780) $(76,860) ======== ======== ======== ======== Net loss attributable to Lexicon Pharmaceuticals, Inc. per common share, basic and diluted $(0.13) $(0.11) $(0.57) $(0.56) ======== ======== ======== ======== Shares used in computing net loss attributable to Lexicon Pharmaceuticals, Inc. per common share, basic and diluted 169,872 136,797 145,465 136,797 Consolidated Balance Sheet Data (In thousands) As of As of December 31, December 31, 2009 2008 ------------ ------------ (unaudited) Cash and investments, including cash and investments held by Symphony Icon, Inc. $162,513 $158,798 Obligations under line of credit (37,435) - -------- -------- Cash and investments, net of obligations under line of credit 125,078 158,798 Property and equipment, net 58,754 65,087 Goodwill 25,798 25,798 Total assets 257,761 261,508 Deferred revenue 15,154 19,884 Current and long-term debt, including line of credit 66,964 30,492 Noncontrolling interest in Symphony Icon, Inc. (290) 10,247 Accumulated deficit
'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Lexicon Announces Proposed Offering of 27,500,000 Shares of Common Stock
2. Lexicon Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
3. Lexicon to Provide Clinical Pipeline Update and Report Second Quarter 2009 Financial Results on July 28, 2009
4. Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome
5. Lexicon Names Ajay Bansal Executive Vice President and Chief Financial Officer
6. Lexicon to Present Clinical Data for LX1031 and LX1032 at Digestive Disease Week
7. Lexicon to Provide Clinical Pipeline Update and Report First Quarter 2009 Financial Results on April 28, 2009
8. Lexicon Pharmaceuticals 2008 Annual Report to Stockholders Available Online
9. Nuevolution Announces Drug Discovery Alliance With Lexicon Pharmaceuticals
10. Lexicon to Report Fourth Quarter and Full Year 2007 Financial Results on March 6, 2008
11. Lexicon Files Investigational New Drug Application for LX1032 as a Potential Treatment for Carcinoid Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... China Biologic Products, Inc. (NASDAQ: CBPO, ... integrated plasma-based biopharmaceutical company in China ... Shandong Taibang Biological Products Co. Ltd., has received ... Food and Drug Administration (the "CFDA") for its ... in the Company,s public filings, the CFDA inspected ...
(Date:12/24/2014)... , Dec. 23, 2014  NeuroLifeSciences announced today ... in children with attention deficit/hyperactivity disorder published in ... The paper, titled "Pilot Phase 2 ... ( Konofal et al, Drug Des Devel ... shows that mazindol might be an effective, well-tolerated, ...
(Date:12/22/2014)... 2014 GenomeDx Biosciences today announced that a ... a genomic test for prostate cancer, was able to ... by radical prostatectomy without adjuvant therapy. Although rapid metastasis ... using tumor genomics to identify these men who have ... important advance. The study has been published online ...
(Date:12/19/2014)... (PRWEB) December 19, 2014 Bioject ... developer and manufacturer of needle-free injection technology, today ... with Immunomic Therapeutics, Inc. (“ITI”) for ITI to ... with its LAMP™ vaccine platform. , In ... exclusive Worldwide license to the Biojector®-2000 that triggers ...
Breaking Biology Technology:China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 2Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 3Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3
... , RICHMOND, Calif., Sept. 16 Sangamo BioSciences, ... Sangamo,s president and CEO, will provide an update on the progress ... company,s business strategy at 1:30 pm ET on Wednesday, September 23, ... held in New York City. , , The ...
... ANTONY, France, September 16 Stallergenes S.A.,has ... trial,(VO59.08) conducted in allergic rhinitis caused by birch pollen and,concerning ... of this pollen, rBet v 1. , ... recombinant allergen as an active,substance. To Stallergenes, knowledge, the use ...
... Sept. 16 /PRNewswire-Asia/ -- Fortis Healthcare, one of ... broaden inclusion,criteria for its upcoming diabetic foot clinical ... peripheral blood to treat critical limb ischemia,(diabetic foot). ... management, risk reduction and lengthy rehabilitation. The current,treatments ...
Cached Biology Technology:Sangamo BioSciences Announces Presentation at the UBS Global Life Sciences Conference 2STALLERGENES: Immunotherapy Tablet Containing Recombinant Allergen (rBet v 1) of Birch Pollen: Positive Results for a Phase IIb/III Trial 2STALLERGENES: Immunotherapy Tablet Containing Recombinant Allergen (rBet v 1) of Birch Pollen: Positive Results for a Phase IIb/III Trial 3STALLERGENES: Immunotherapy Tablet Containing Recombinant Allergen (rBet v 1) of Birch Pollen: Positive Results for a Phase IIb/III Trial 4Indian Stem Cell Trial to Broaden Diabetic Foot Inclusion Criteria 2Indian Stem Cell Trial to Broaden Diabetic Foot Inclusion Criteria 3Indian Stem Cell Trial to Broaden Diabetic Foot Inclusion Criteria 4
(Date:12/22/2014)...  NXT-ID, Inc. (NASDAQ: NXTD and ... focused on the growing mobile commerce market, announces it ... Apollo Robbins for the 2015 International CES debut ... Apollo Robbins will be at the NXT-ID ... some of his famous theft techniques to visiting media ...
(Date:12/22/2014)...  The 2014 Holiday Season may be the ... Market Intelligence reports that the long anticipated floodgates ... forecasts that intensifying demand for smart phones, tablets, ... drive a global market of 2.5 billion users ... According to Maxine Most ...
(Date:12/19/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/86ncd6/micro_market ) has ... North America Perimeter Security Systems Market" report to ... The North American perimeter security market is ... 2014 to 2019. Although the U.S. market holds a ... is expected to grow at a higher CAGR ...
Breaking Biology News(10 mins):NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 4First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3
... WI, SEPTEMBER 7, 2010 The American Society of ... Soil Science Society of America (SSSA) will present the ... on Oct. 31-Nov. 3 in Long Beach, CA, ... , , The Hank Beachell Future Leader ...
... research on how genes affect responses to medicines, the National ... to expand a key resource, the Pharmacogenomics Knowledge Base (PharmGKB), ... is to use information about a patient,s genetic make-up to ... grown, so has PharmGKB. Begun in 2000 to catalog links ...
... St. Louis, MO Current research provides a novel ... LaBranche et al, "Characterization of the KRN cell transfer model ... the K/BxN mouse," appears in the September 2010 issue of ... of the population is affected by rheumatoid arthritis, and women ...
Cached Biology News:ASA, CSSA and SSSA present scholarships and fellowships 2ASA, CSSA and SSSA present scholarships and fellowships 3ASA, CSSA and SSSA present scholarships and fellowships 4ASA, CSSA and SSSA present scholarships and fellowships 5ASA, CSSA and SSSA present scholarships and fellowships 6ASA, CSSA and SSSA present scholarships and fellowships 7ASA, CSSA and SSSA present scholarships and fellowships 8ASA, CSSA and SSSA present scholarships and fellowships 9NIH expands key pharmacogenomics resource 2Casing the joint 2
... Butcher (1998). • The major histocompatibility complex ... the immunology area. There is great interest ... in their function as antigen-presenting molecules. Many ... prospect of tackling biochemical and genetic techniques ...
actin from rabbit muscle Cell Biology Cytoskeletal Probes Actin and Actin Probes...
... 71-18 mutS and ES1301 mutS are mismatch ... of these strains prevents repair of the ... high mutation efficiencies and making them helpful ... Altered Sites II Mutagenesis Systems. Both ES1301 ...
propidium iodide *1.0 mg/mL solution in water*...
Biology Products: